Resistance to HIV protease inhibitors

Haemophilia

Volumn 4, Issue 4, 1998, Pages 610-615

  Condra, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

141W94; Drug resistance; Indinavir; Nelfinavir; Ritonavir; Saquinavir

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; PROTEINASE; PROTEINASE INHIBITOR;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CONFERENCE PAPER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031856659     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.1998.440610.x     Document Type: Conference Paper

References (24)

1. Condra JH, Emini EA. Preventing HIV-1 drug resistance. Science & Medicine 1997; 4(1): 14-23.
2. Condra JH, Schleif WA, Blahy OM, et al. In-vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374(6522) :569-71.
3. Condra JH, Holder DJ, Schleif WA, et al. Genetic correlates of in-vivo viral resistance to indinavir, a human immunodeficiency virus type-1 protease inhibitor. J Virol 1996; 70(12): 8270-6.
4. Schock HB, Garsky VM, Kuo LC. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical-trials - compensatory modulations of binding and activity. J Biol Chem 1996; 271(50): 31957-63.
5. Jacobsen H, Haenggi M, Ott M, et al. Reduced sensitivity to saquinavir - an update on genotyping from phase I/II trials. Antivir Res 1996; 29(1): 95-7.
6. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996; 2(7): 760-6.
7. Schmit JC, Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996; 10(9): 995-9.
8. Patick AK, Markowitz M, Appelt K, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human-immunodeficiency-virus protease. Antimicrob Agents Chemother 1996; 40(2): 292-7.
9. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. Antivir Ther 1996; 1 (Suppl 1): 17-8.
10. Smith T, Swanstrom R. Selection for high-level resistance to HIV-1 protease inhibitors used in pairs. Antivir Ther 1996; 1 (Suppl 1): 12-3.
11. Partaledis JA, Yamaguchi K, Tisdale M, et al. In-vitro selection and characterization of human-immunodeficiency-virus type-1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995; 69(9): 5228-35.
12. Kozal MJ, Shah N, Shen NP, et al. Extensive polymorphisms observed in HIV-1 clade-b protease gene using high-density oligonucleotide arrays. Nature Med 1996; 2(7): 753-9.
13. Coffin JM. HIV Population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995; 267: 483-9.
14. Condra JH, Schleif WA, Blahy OM, et al. Evidence for the existence of long-lived genetic reservoirs of HIV-1 in infected patients. J Acq Immun Def Synd Hum Retrovirol 1995; 10(3): 82.
15. Condra JH, Holder DJ, Graham DJ, et al. Genotypic or phenotypic susceptibility testing may not predict clinical responses to indinavir. Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication 1997; 31-2; Abstract 47.
16. Boucher C. Rational approaches to resistance - using saquinavir. AIDS 1996; 10(1): S15-S19.
17. Tisdale M, Myers RE, Maschera B, Parry N, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995; 39(8): 1704-10.
18. Smith T, Swanstrom R. Biological cross-resistance to HIV-1 protease inhibitors. Abstracts of the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, St. Petersburg, Florida. 1997:10, Abstract 15.
19. Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Feb. 1-5, 1998, Chicago, IL 1998: 153, Abstract 395.
20. Vacca JP, Condra JH. Clinically effective HIV-1 protease inhibitors. Drug Discov Today 1997; 2(7): 261-72.
21. Rachlis AR, Palmer RH, Bast M, Robinson G, Logue K, Klein A. Predictors of decreases in plasma HIV-1 RNA in patients treated with indinavir. Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario. 1997; Abstract A-17.
22. Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario 1997; Abstract LB-2.
23. Henry K, Kane E, Melroe H, Simpson J, Patick A, Winslow D. Experience with a ritonavir/saquinavir based regimen for the treatment of HIV infection in subjects developing increased viral loads while receiving nelfinavir. Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario 1997; Abstract I-204.
24. Sampson MS, Barr MR, Torres RA, Hall G. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression. Abstracts of 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Ontario 1997; Abstract LB-5.